Profile data is unavailable for this security.
About the company
RELIEF THERAPEUTICS Holding SA is a Switzerland-based biopharmaceutical company. The Company’s objective is to provide patients with therapeutic relief in serious diseases with high unmet medical need, as well as to focus on developing treatments for respiratory diseases. It specializes in clinical-stage projects based on molecules of natural origin (peptides and proteins with a history of clinical use and either initial human activity with efficacy data or a strong scientific rationale. Its lead compound is RLF-100 (aviptadil), a synthetic human vasoactive intestinal peptide (VIP) with a multifaceted mode of action in respiratory indications. RLF-100 is being investigated in two placebo-controlled U.S. phase 2b/3 clinical trials in respiratory deficiency due to COVID-19. Its RLF-100 is also used for pulmonary sarcoidosis. The Company is also involved in the clinical development of RLF-100 that is in planning stage for other indications in acute and chronic lung diseases.
- Revenue in CHF (TTM)5.86m
- Net income in CHF-80.79m
- Incorporated2017
- Employees64.00
- LocationRelief Therapeutics Holding SAAvenue de Secheron 15GENEVE 1202SwitzerlandCHE
- Phone+41 447235959
- Fax+41 447269012
- Websitehttps://relieftherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SMAIO SA | 5.88m | -877.54k | 15.70m | 38.00 | -- | 1.42 | 29.85 | 2.67 | -0.1707 | -0.1707 | 1.16 | 2.18 | 0.4249 | 0.1668 | 14.23 | 195,029.40 | -6.34 | -- | -7.62 | -- | 96.36 | -- | -14.93 | -- | 3.39 | -7.82 | 0.1276 | -- | 14.64 | -- | 191.89 | -- | -- | -- |
| Vytrus Biotech SA | 3.63m | 529.72k | 16.46m | 36.00 | 29.48 | 3.03 | 13.33 | 4.53 | 0.0807 | 0.0807 | 0.5548 | 0.7857 | 0.4316 | 1.23 | 6.65 | 103,803.90 | 6.29 | 5.24 | 7.24 | 5.93 | 83.62 | 88.31 | 14.58 | 13.26 | 1.90 | 2.96 | 0.282 | -- | 1.48 | 33.30 | -9.97 | -- | -- | -- |
| Circa Group AS | 1.63m | -5.66m | 16.63m | 18.00 | -- | 0.5393 | -- | 10.20 | -0.5953 | -0.5953 | 0.1716 | 3.05 | 0.042 | -- | 0.9809 | -- | -14.56 | -- | -17.56 | -- | 80.17 | -- | -346.99 | -- | 1.99 | -- | -- | -- | 41.82 | -- | 2.46 | -- | -- | -- |
| Provexis plc | 678.05k | -562.99k | 16.68m | 2.00 | -- | 14.67 | -- | 24.59 | -0.0002 | -0.0002 | 0.0003 | 0.0004 | 0.6717 | 3.04 | 2.95 | 299,040.00 | -55.78 | -48.82 | -41.86 | -33.68 | 46.72 | 86.14 | -83.03 | -97.64 | 1.96 | -- | 0.00 | -- | -8.51 | 10.58 | -71.79 | -- | -- | -- |
| Saniona AB | 1.40m | -7.98m | 16.91m | 23.00 | -- | -- | -- | 12.06 | -1.28 | -1.28 | 0.226 | -0.2895 | 0.1546 | -- | 4.71 | 732,173.90 | -87.96 | -59.16 | -108.11 | -70.15 | -213.08 | -970.05 | -568.94 | -1,483.55 | -- | -3.18 | 1.44 | -- | 10.19 | -21.05 | 54.71 | -- | -34.94 | -- |
| Active Biotech AB publ | 0.00 | -3.81m | 16.99m | 11.00 | -- | 6.65 | -- | -- | -0.1536 | -0.1536 | 0.00 | 0.0849 | 0.00 | -- | -- | -- | -96.42 | -57.97 | -126.27 | -97.84 | -- | -- | -- | -1,454.61 | -- | -- | 0.089 | -- | -- | -- | 21.54 | -- | -- | -- |
| RELIEF THERAPEUTICS Holding SA | 5.86m | -80.79m | 17.06m | 64.00 | -- | 0.1573 | -- | 2.91 | -7.36 | -7.36 | 0.537 | 7.72 | 0.0337 | 3.92 | 2.92 | 84,956.52 | -46.48 | -20.45 | -49.26 | -22.13 | 76.80 | -- | -1,378.18 | -1,015.54 | 2.23 | -- | 0.046 | -- | 83.11 | -- | -46.35 | -- | -- | -- |
| Phaxiam Therapeutics SA | 1.29m | -22.83m | 17.42m | 51.00 | -- | 0.6997 | -- | 13.52 | -5.56 | -5.56 | 0.3139 | 4.22 | 0.0273 | -- | 14.82 | 26,000.00 | -48.37 | -50.69 | -66.94 | -66.25 | -- | -- | -1,771.42 | -1,009.09 | -- | -70.21 | 0.3412 | -- | -80.05 | -21.50 | -10,201.75 | -- | -56.68 | -- |
| Genincode PLC | 1.95m | -7.63m | 17.55m | 28.00 | -- | 1.76 | -- | 9.02 | -0.0703 | -0.0703 | 0.0179 | 0.0497 | 0.168 | 16.36 | 2.88 | 61,285.71 | -65.92 | -- | -72.37 | -- | 47.55 | -- | -392.31 | -- | 5.85 | -- | 0.0632 | -- | 23.92 | -- | -34.21 | -- | -- | -- |
| Valerio Therapeutics SA | 1.40m | -19.18m | 17.74m | 39.00 | -- | 0.7858 | -- | 12.64 | -0.1811 | -0.1811 | 0.0134 | 0.1504 | 0.0287 | -- | 0.7024 | 57,720.00 | -39.19 | -25.87 | -51.38 | -30.65 | 66.04 | 89.79 | -1,367.57 | -381.62 | -- | -586.70 | 0.2913 | -- | -64.48 | -31.41 | -229.49 | -- | 49.66 | -- |
| Exact Therapeutics AS | 0.00 | -2.98m | 18.07m | 8.00 | -- | 4.53 | -- | -- | -1.20 | -1.20 | 0.00 | 1.50 | 0.00 | -- | -- | -- | -49.19 | -33.93 | -57.46 | -38.22 | -- | -- | -- | -- | -- | -- | 0.031 | -- | -- | -- | 31.55 | -- | -- | -- |
| NicOx SA | 3.47m | -16.87m | 18.21m | 11.00 | -- | 0.4081 | -- | 5.24 | -0.3721 | -0.3721 | 0.0753 | 0.9128 | 0.0394 | -- | 1.83 | 324,909.10 | -19.13 | -19.22 | -21.35 | -20.78 | -- | -- | -485.70 | -370.14 | -- | -- | 0.3172 | -- | -54.78 | 7.25 | 36.57 | -- | -13.35 | -- |
| Abliva AB | 11.41k | -7.95m | 18.29m | 6.00 | -- | 2.44 | -- | 1,603.44 | -0.0904 | -0.0904 | 0.0001 | 0.067 | 0.001 | -- | 0.0034 | -- | -70.40 | -74.59 | -80.95 | -86.98 | -14,491.24 | -- | -69,715.33 | -65,958.89 | -- | -- | -- | -- | 341.94 | 93.89 | -12.02 | -- | -19.74 | -- |
| Chill Brands Group PLC | 166.22k | -4.13m | 18.34m | 2.00 | -- | -- | -- | 110.30 | -0.0142 | -0.0142 | 0.0006 | -0.0024 | 0.0319 | 0.0992 | 0.3639 | 73,310.00 | -79.21 | -72.55 | -141.46 | -105.35 | 53.05 | -- | -2,485.30 | -1,625.46 | 0.6499 | -8.48 | 1.17 | -- | -86.73 | -50.89 | 23.50 | -- | -35.95 | -- |
| Nfl Biosciences SAS | 0.00 | -3.39m | 18.43m | 3.00 | -- | 4.81 | -- | -- | -0.5396 | -0.5396 | 0.00 | 0.4097 | 0.00 | -- | -- | 0.00 | -80.79 | -- | -125.59 | -- | -- | -- | -- | -- | -- | -- | 0.0228 | -- | -- | -- | -149.78 | -- | -- | -- |
Data as of Apr 18 2024. Currency figures normalised to Relief Therapeutics Holding SA's reporting currency: Swiss Franc CHF
10.77%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Armistice Capital LLCas of 27 Jun 2023 | 1.20m | 8.55% |
| Credit Suisse Asset Management (Schweiz) AGas of 29 Feb 2024 | 83.16k | 0.59% |
| Herculis Partners SAas of 31 Jan 2020 | 82.50k | 0.59% |
| UBS Asset Management Switzerland AGas of 02 Apr 2024 | 54.88k | 0.39% |
| Z�rcher Kantonalbank (Investment Management)as of 29 Feb 2024 | 49.25k | 0.35% |
| Pictet Asset Management SAas of 30 Nov 2023 | 19.64k | 0.14% |
| Credit Suisse AGas of 31 Jan 2024 | 8.81k | 0.06% |
| BlackRock Asset Management Schweiz AGas of 04 Apr 2024 | 6.26k | 0.05% |
| British & American Investment Trust Plc (Invt Mgmt)as of 30 Jun 2023 | 4.54k | 0.03% |
| Lombard Odier Asset Management (Switzerland) SAas of 29 Feb 2024 | 3.49k | 0.03% |
More ▼
Data from 30 Jun 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
